Showing 5891-5900 of 7140 results for "".
- Valeant Terminates European Licensing Rights for Brodalumabhttps://practicaldermatology.com/news/valeant-terminates-european-licensing-rights-for-brodalumab/2458512/Valeant Pharmaceuticals International, Inc.'s affiliate and AstraZeneca have amended Valeant's license for brodalumab, an IL-17 receptor monoclonal antibody under regulatory review for patients with moderate-to-severe plaque psoriasis, to terminate Valeant's right to develop and comme
- Daily ‘Soak and Smear' OKed for Kids with Eczemahttps://practicaldermatology.com/news/daily-soak-and-smear-oked-for-kids-with-eczema/2458513/Daily bathing is fine for children with eczema as long as it's followed by lots of moisturizer, according to a new article in Annals of Allergy, Asthma and Immunology. Researchers led by Portl
- Global Psoriasis Survey: 85% of US Respondents Faced Social Stigma Because of Psoriasishttps://practicaldermatology.com/news/global-psoriasis-survey-85-of-us-respondents-faced-social-stigma-because-of-psoriasis/2458514/Novartis released new results from its Clear About Psoriasis Survey, the largest global survey to date of people with moderate-to-severe psoriasis. Findings reveal 85 percent of US respondents have suffered from social stigma like discrimination and humiliation because of their disease. In additi
- Novel Impetigo Drug on the Horizonhttps://practicaldermatology.com/news/new-impetigo-drug-on-the-horizon/2458518/Medimetriks Pharmaceuticals, Inc. submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ozenoxacin cream, 1%, a novel, non-fluorinated quinolone for the treatment of impetigo. Medimetriks licensed e
- Analysis Uncovers Health Economic Data for H.P. Acthar® Gel in Dermatomyositis and Polymyositishttps://practicaldermatology.com/news/analysis-uncover-health-economic-data-for-hp-acthar-gel-in-dermatomyositis-and-polymyositis/2458519/Results from two retrospective analyses sponsored by Mallinckrodt plc show that use of the company’s H.P. Acthar® Gel (repository corticotropin injection) offers a cost-effec
- Sciton Introduces diVa Laser for Vaginal Rejuvenationhttps://practicaldermatology.com/news/sciton-introduced-diva-laser-for-vaginal-rejuvenation/2458524/Sciton introduced diVa, a hybrid fractional laser (HFL) for the treatment of vaginal tissue. Major life events like childbirth and menopause can cause changes in vaginal health. Excessive stretching of the vaginal tissue commonly happens from childbirth. Vaginal tissue may not fully recov
- New Hair Restoration Group Started for Dermatologists, Facial Plastic Surgeons and Plastic Surgeonshttps://practicaldermatology.com/news/new-hair-restoration-group-started-for-dermatologists-facial-plastic-surgeons-and-plastic-surgeons/2458525/Introducing The North American Society for Hair Restoration (NASHR), a new non-profit medical association comprising plastic surgeons, facial plastic surgeons and dermatologists who have the proper training for hair transplantation surgery.
- Changes Afoot at Valeant Pharmaceuticalshttps://practicaldermatology.com/news/changes-afoot-at-valeant-pharmaceuticals/2458527/Amid reports that its Obagi Medical Products and Solta Medical units are on the block, Valeant Pharmaceuticals is assuring investors that the company is focused on the future and has plans to fix its dermatology unit. Valeant CEO Joseph Papa cite
- Valeant Pharmaceuticals Appoints Thomas W. Ross, Sr. Lead Independent Directorhttps://practicaldermatology.com/news/valeant-pharmaceuticals-appoints-thomas-w-ross-sr-lead-independent-director/2458532/Valeant Pharmaceuticals International, Inc.'s Board of Directors appointed Thomas W. Ross, Sr. as its lead independent director. Mr. Ross, who has been a member of Valeant's Board since March 8, 2016, serves on the Board&#
- UCB: Investigational Bimekizumab Helps Psoriatic Arthritis in Phase 1Bhttps://practicaldermatology.com/news/ucb-investigational-bimekizumab-helps-psoriatic-arthritis-in-phase-1b/2458534/Bimekizumab, in development by UCB, has shown promise for the treatment of psoriatic arthritis (PsA) in Phase 1B studies. For the study, a total of 52 PsA patients inadequately controlled with at least one disease-modifying anti-rheumatic drug (DMARD) and/or one biologic were randomized to